ZSVC

Headquartered in Hangzhou, ZSVC operates as a regional venture firm tapping into Zhejiang province’s broader technology and manufacturing ecosystem. The firm’s healthcare activity spans biotech and digital health, leveraging proximity to advanced materials research and biomedical innovation clusters that have grown alongside the area’s well-known consumer technology base. Public information about ZSVC’s strategy and team is limited, but the firm is positioned as a strategically anchored investor for companies seeking exposure to the Yangtze Delta scientific community rather than purely Beijing or Shanghai capital.

ZSVC concentrates on Series A and Series B rounds, writing checks generally in the one to five million dollar range. Activity is centered on mainland China, with capital deployed alongside provincial industrial and academic partners that have helped Zhejiang become a hub for life science commercialization. Founders should expect the firm to be most useful when their company has already validated initial science or product-market fit and is preparing to scale manufacturing, regulatory, or commercial operations within China.

The partner roster and detailed engagement model are not extensively documented in public sources, so prospective founders will need to rely on warm introductions through portfolio operators or local ecosystem partners. Limited public information means the firm’s level of board involvement, follow-on philosophy, and decision timelines are best confirmed directly. Companies whose science or product strategy benefits from Zhejiang-based supply chains, hospital networks, or research institutions are likely the strongest fit, particularly if they need a domestic financial partner with regional industrial fluency rather than a coastal mega-fund.